业界动态国内医卫资讯

FDA批准首创药物Asundexian用于卒中预防

Medscape News · 2026-11-11 00:36

摘要

Asundexian成为首个获FDA批准的第XIa因子抑制剂,为在抗血小板治疗基础上预防复发性缺血性卒中提供了新选择。Medscape Medical News

English
FDA Approves First-in-Class Asundexian for Stroke Prevention

Asundexian becomes the first FDA-approved factor XIa inhibitor, offering a new option for preventing recurrent ischemic stroke when added to antiplatelet therapy. Medscape Medical News

内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界